{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Q4W+placebo+IV+injections", "query": { "intervention": "Q4W placebo IV injections" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T17:38:57.187Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06602258", "title": "A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "E2814", "type": "DRUG" }, { "name": "Lecanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 105, "start_date": "2024-09-30", "completion_date": "2027-08-18", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 18, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Bradenton, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Clermont", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06602258" }, { "nct_id": "NCT01768572", "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" }, { "name": "subcutaneous placebo", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768572" }, { "nct_id": "NCT04503733", "title": "A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Q4W GMA301 IV injections (300 mg)", "type": "DRUG" }, { "name": "Q4W GMA301 IV injections (600 mg)", "type": "DRUG" }, { "name": "Q4W GMA301 IV injections (1000 mg)", "type": "DRUG" }, { "name": "Q4W GMA301 IV injections (1800 mg)", "type": "DRUG" }, { "name": "Q4W placebo IV injections", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gmax Biopharm LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 48, "start_date": "2020-10-22", "completion_date": "2023-06-10", "has_results": false, "last_update_posted_date": "2022-01-14", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04503733" }, { "nct_id": "NCT03887455", "title": "A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Alzheimer's Disease" ], "interventions": [ { "name": "Lecanemab IV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Lecanemab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 1906, "start_date": "2019-03-27", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 112, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03887455" }, { "nct_id": "NCT07599670", "title": "A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "ABBV-1758", "type": "DRUG" }, { "name": "Placebo for ABBV-1758", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 210, "start_date": "2026-05-15", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 11, "location_summary": "Irvine, California • Boulder, Colorado • Bradenton, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Clermont", "state": "Florida" }, { "city": "Lady Lake", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07599670" }, { "nct_id": "NCT06196203", "title": "A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Higher-risk Myelodysplastic Syndromes" ], "interventions": [ { "name": "AK117", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akeso", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-02-07", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 14, "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orange City", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06196203" }, { "nct_id": "NCT01951586", "title": "Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Denosumab", "type": "DRUG" }, { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "Placebo to Denosumab", "type": "DRUG" }, { "name": "Standard Chemotherapy", "type": "DRUG" }, { "name": "Placebo to Zoledronic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 226, "start_date": "2013-12-31", "completion_date": "2017-11-28", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 18, "location_summary": "Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951586" }, { "nct_id": "NCT05075824", "title": "A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Crovalimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "12 Years to 55 Years" }, "enrollment_count": 95, "start_date": "2022-03-09", "completion_date": "2026-04-09", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 4, "location_summary": "Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Madison", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05075824" }, { "nct_id": "NCT07647510", "title": "A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthenia Gravis, Generalized" ], "interventions": [ { "name": "Claseprubart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Claseprubart", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Dianthus Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 195, "start_date": "2026-06-29", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 4, "location_summary": "Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Fayetteville", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07647510" }, { "nct_id": "NCT02620020", "title": "A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Low Back Pain" ], "interventions": [ { "name": "Fasinumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 563, "start_date": "2016-01-26", "completion_date": "2017-09-13", "has_results": true, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-10-01T17:38:57.187Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02620020" } ] }